Biomarkers
Providing expertise in the analysis of biomarkers in preclinical and clinical development.
Biomarkers are now an integral part of industry efforts to streamline drug development. They are increasingly important in helping "go/no go" decisions in early phase preclinical and clinical development, either as indicators of safety or efficacy.
Quotient Bioresearch can provide our clients with a breadth of capabilities offering choice spanning from biomarker discovery, assay development, validation and sample analysis supporting preclinical and clinical development programmes.
We offer a range of biomarker services which can be adapted to your drug development, drug surveillance or other clinical research or monitoring needs.
- Biomarker discovery - including metabonomics and metabolomics and mass spectrometry of the proteome
- Method development – feasibility assessment, establishing methods and development. We are experienced with a variety of analytical methodologies, species and matrices.
- Validation of biomarker methods – validation of both in-house and commercial biomarker methods to GCP/GLP standards
- Biomarker quantification – as a measure of drug safety or efficacy, or to prove a new drug’s mechanism. We have experience of a range of proteins, peptides, antibodies, small molecules, cytokines – and more
- Methods and instrumentation – our cutting-edge labs are equipped with the latest technology, including our unique BioMS™ service, Gyrolab™, and MSD™ as well as electrophoresis, affinity chromatography, mass spectrometry and fluorescence/chemiluminescence/radiolabel techniques
- Our experience – we have been pioneering biomarker research for sports drug surveillance for more than 10 years.
GCP - Good Clinical Practice; GLP - Good Laboratory Practice; BioMS™ - Biologicals measured by mass spectrometry; MSD™ - Meso Scale Discovery